AMGN image

Amgen, Inc. (AMGN) Is On The Prowl For Acquisition Targets

AMGN – Amgen says it’s looking hard for acquisitions that make sense, but inflated valuations are proving to make deal-making difficult.


Amgen, Inc. (NASDAQ:AMGN) wants to acquire one or more key biotech companies, but deal-making is difficult in today’s high-valuation environment.

That’s the message the company sent to investors this week, as it remains on the prowl to find deals that make sense to help grow its porfolio. CNBC has more details:

Amgen, the world’s largest biotech company, has said it is “looking hard” for deals to deploy its $27bn cash pile but warned it is struggling to find targets amid soaring valuations in the life sciences sector.

The note of caution comes as mergers and acquisitions activity in the healthcare sector recorded its strongest start to a year in more than a decade, with almost $32bn of global deals announced since the start of January.

In order to get deals in the space done, buyers have had to pony up sky-high premiums. For example, Celgene’s recent acquisition of Juno for $9 billion was a nearly 100% markup to the company’s pre-deal valuation.

“We want to deploy any excess cash and our first priority is to do acquisitions and invest in the business,” Amgen CFO David Meline told the Financial Times recently. However, “We see all of these deals announced, and we participate pretty actively in considering whether to bid, but we haven’t been able to come up with a business case that would make a return for our shareholders.”

For now, AMGN plans to keep looking — but the company isn’t willing to pay a price beyond what it feels it can earn a good return on.

Amgen, Inc. shares were unchanged in premarket trading Tuesday. Year-to-date, AMGN has gained 0.56%, versus a -0.57% rise in the benchmark S&P 500 index during the same period.

AMGN currently has a StockNews.com POWR Rating of C (Neutral), and is ranked #61 of 294 stocks in the Biotech category.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

AMGN at a Glance

AMGN Current POWR Rating™
Overall POWR Rating™
AMGN Current Price $202.34 3.45%
More AMGN Ratings, Data, and News

AMGN Price Reaction

The day of this event (Feb. 13, 2018)
AMGN Closing Price$172.11 0.61%
AMGN Volume3,920,009
19.04% from avg
Leading up to this event
AMGN 1-mo returnN/A%
After this event
AMGN 1-day return3.32%
AMGN 3-day return5.44%
AMGN 5-day return4.86%

AMGN Price Chart



More Amgen Inc. (AMGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AMGN News
Page generated in 1.1381 seconds.